Review



ngf neutralizing antiserum  (Cedarlane)


Bioz Verified Symbol Cedarlane is a verified supplier
Bioz Manufacturer Symbol Cedarlane manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 85
      Buy from Supplier

    Structured Review

    Cedarlane ngf neutralizing antiserum
    Ngf Neutralizing Antiserum, supplied by Cedarlane, used in various techniques. Bioz Stars score: 85/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ngf neutralizing antiserum/product/Cedarlane
    Average 85 stars, based on 5 article reviews
    ngf neutralizing antiserum - by Bioz Stars, 2026-05
    85/100 stars

    Images



    Similar Products

    ngf neutralizing antiserum  (Cedarlane)
    85
    Cedarlane ngf neutralizing antiserum
    Ngf Neutralizing Antiserum, supplied by Cedarlane, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ngf neutralizing antiserum/product/Cedarlane
    Average 85 stars, based on 1 article reviews
    ngf neutralizing antiserum - by Bioz Stars, 2026-05
    85/100 stars
    		  Buy from Supplier
    a neutralizing antiserum against ngf receptor trka  (Millipore)
    90
    Millipore a neutralizing antiserum against ngf receptor trka
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    A Neutralizing Antiserum Against Ngf Receptor Trka, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a neutralizing antiserum against ngf receptor trka/product/Millipore
    Average 90 stars, based on 1 article reviews
    a neutralizing antiserum against ngf receptor trka - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    ngf neutralizing antiserum  (Millipore)
    90
    Millipore ngf neutralizing antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Ngf Neutralizing Antiserum, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ngf neutralizing antiserum/product/Millipore
    Average 90 stars, based on 1 article reviews
    ngf neutralizing antiserum - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    ngf-neutralizing antiserum  (Millipore)
    90
    Millipore ngf-neutralizing antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Ngf Neutralizing Antiserum, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ngf-neutralizing antiserum/product/Millipore
    Average 90 stars, based on 1 article reviews
    ngf-neutralizing antiserum - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    ngf-neutralizing antiserum  (Cedarlane)
    90
    Cedarlane ngf-neutralizing antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Ngf Neutralizing Antiserum, supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ngf-neutralizing antiserum/product/Cedarlane
    Average 90 stars, based on 1 article reviews
    ngf-neutralizing antiserum - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    neutralizing anti-ngf antiserum  (Harlan Laboratories)
    90
    Harlan Laboratories neutralizing anti-ngf antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Neutralizing Anti Ngf Antiserum, supplied by Harlan Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neutralizing anti-ngf antiserum/product/Harlan Laboratories
    Average 90 stars, based on 1 article reviews
    neutralizing anti-ngf antiserum - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor (NGF) receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A (trkA) receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.

    Journal: Immunology

    Article Title: Lipopolysaccharide induces calcitonin gene-related peptide in the RAW264.7 macrophage cell line

    doi: 10.1111/j.1365-2567.2009.03239.x

    Figure Lengend Snippet: Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor (NGF) receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A (trkA) receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.

    Article Snippet: A neutralizing antiserum against NGF receptor trkA was obtained from Chemicon Inc. (Temecula, CA).

    Techniques: Activity Assay